Lilly’s Olumiant flunks COVID-19 trial – or does it?Eli Lilly’s JAK inhibitor Olumiant has missed its main objective in a phase 3 trial in hospitalised COVID-19 Share XLilly’s Olumiant flunks COVID-19 trial – or does it?https://pharmaphorum.com/news/lillys-olumiant-flunks-covid-19-trial-or-does-it/
Gilead/Galapagos alliance hit again as IPF drug is binnedGilead and Galapagos’ much-trumpeted R&D alliance has suffered another setback with the abandonment of ziritaxestat after a late-stage Share XGilead/Galapagos alliance hit again as IPF drug is binnedhttps://pharmaphorum.com/news/gilead-galapagos-alliance-hit-again-as-ipf-drug-is-binned/
Gilead says Veklury should work against COVID-19 variantsGilead Sciences says its antiviral Veklury should be effective against the new, more contagious COVID-19 variants discovered in Share XGilead says Veklury should work against COVID-19 variantshttps://pharmaphorum.com/news/gilead-says-veklury-should-work-against-covid-19-variants/
Oxford BioTherapeutics to research cell therapies for Gilead’s KiteGilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch Share XOxford BioTherapeutics to research cell therapies for Gilead’s Kitehttps://pharmaphorum.com/news/oxford-biotherapeutics-to-research-cell-therapies-for-gileads-kite/
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirGilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug Share XData sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirhttps://pharmaphorum.com/news/data-sets-up-2021-filings-for-gileads-twice-a-year-hiv-drug-lenacapavir/
Gilead Q3 revenue rise bolstered by $873m Veklury salesGilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment Share XGilead Q3 revenue rise bolstered by $873m Veklury saleshttps://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/
BioSig abandons COVID-19 drug trial on safety concernsUS biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury Share XBioSig abandons COVID-19 drug trial on safety concernshttps://pharmaphorum.com/news/biosig-abandons-covid-19-drug-trial-on-safety-concerns/
Kite cues up first EMA okay for mantle cell lymphoma CAR-TGilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for Share XKite cues up first EMA okay for mantle cell lymphoma CAR-Thttps://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/
EU ramps up supply of COVID-19 vaccine, drugsThe European Commission has taken its advance orders for potential COVID-19 vaccines to more than 1.1 billion, after Share XEU ramps up supply of COVID-19 vaccine, drugshttps://pharmaphorum.com/news/eu-ramps-up-supply-of-covid-19-vaccine-drugs/
